Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen’s® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS

by Barry101 | Aug 23, 2019 | Press Release, Uncategorized

Announces new ticker symbol ‘AIM’ effective September 3, 2019OCALA, Fla., Aug. 23, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-tech company focused on the research and development of immunological agents to treat multiple types...

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials

by Barry101 | Aug 15, 2019 | Press Release, Uncategorized

OCALA, Fla., Aug. 15, 2019 — Hemispherx Biopharma, Inc. (NYSE American: HEB), an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency diseases, announces the filing of its report...

Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen®

by Barry101 | Aug 8, 2019 | Press Release, Uncategorized

OCALA, Fla., Aug. 08, 2019 — Hemispherx Biopharma (NYSE American: HEB) announced today that the University of Pittsburgh Medical Center (UPMC) has issued a final report supporting the safety of using Ampligen in combination therapy for the treatment of recurrent...

Hemispherx Secures Corrections from Two Stock News Organizations Related to Their Inaccurate Reporting of an Equity Distribution Agreement Disclosed in a Recent SEC Filing

by Barry101 | Aug 2, 2019 | Press Release

OCALA, Fla., Aug. 02, 2019 — Hemispherx Biopharma (NYSE American: HEB) recently demanded and received retractions and corrections in two cases of inaccurate reporting due to AI algorithms following the filing of an 8-K on July 22, 2019. The two stock news...